Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • VAC2
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu
  • Investors

    Lineage is a clinical-stage biotechnology company developing novel cell therapies

Investors

NYSE AMERICAN: LCTX

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 
VIEW STOCK QUOTE
Press Releases
November 29, 2022
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 28, 2022
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
November 10, 2022
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
VIEW PRESS RELEASES
Events & Presentations
Lineage Cell Therapeutics Corporate Overview January 23, 2023 5.4 MB
Roche’s Pharma Day 2022
Third Quarter 2022 Financial Results Earnings Call
Nov 10, 2022 at 4:30 PM EST
Click here for webcast
VIEW EVENTS & PRESENTATIONS
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top